Show simple item record

AuthorEl Gamal, Heba
AuthorMunusamy, Shankar
Available date2017-01-11T05:55:34Z
Publication Date2017-01
Citation"Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges", 2017, Vol. 24, numb. 1, El Gamal. Heba ,Munusamy. Shankar, Protein & Peptide Letters.
AbstractDiabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes mellitus and the leading cause of end stage renal disease. One of the key pathways activated in DN is the polyol pathway, in which glucose is converted to sorbitol (a relatively non-metabolizable sugar) by the enzyme aldose reductase (AR). Shunting of glucose into this pathway causes disruption to glucose metabolism and subsequently damages the tissues via increased oxidative stress, protein kinase c activation and production of advanced glycation end products (AGE) in the kidney. This review aims to provide a comprehensive overview of the AR enzyme structure, substrate specificity and topology in normal physiology; to elaborate on the deleterious effects of AR activation in DN; and to summarize the potential therapeutic benefits and major challenges associated with AR inhibition in patients with DN.
SponsorOffice of Academic Research, Qatar University for their support through intramural grants (# QUST-CPH-SPR-12/13-4, QUST-CPH-FALL-13/14-5, QUST-CPH- SPR-13/14-7, QUST-CPH-FALL-14/15-6, QUST-CPH-SPR-14/15-15).
PublisherBentham Science Publishers
SubjectDiabetic Nephropathy
SubjectPolyol Pathway
SubjectProtein Kinase C
SubjectOxidative Stress
SubjectAdvanced Glycation End products
SubjectAldose Reductase
TitleAldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
Issue Number1
Volume Number24

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record